Why China Represents a Compelling Strategic Opportunity for Global Biotech
China has emerged as one of the most attractive markets for international biotech companies seeking to accelerate clinical development and optimize regulatory pathways. With the largest patient population in the world, sponsors can achieve significantly faster enrollment in oncology, immunology, respiratory, rare diseases, and other therapeutic areas.
The NMPA has implemented progressive reforms that increasingly align with FDA and EMA standards, enabling smoother pre-IND/IND interactions, expedited review pathways for innovative modalities (including mRNA/DNA therapeutics, bispecific antibodies, and novel vaccines), and greater acceptance of multi-regional clinical trial (MRCT) data.
Combined with cost-efficient high-quality trial execution, robust KOL networks, and strong government support for biotech innovation, China offers a powerful platform to generate pivotal data, de-risk global programs, and unlock substantial commercial upside in the world’s second-largest pharmaceutical market — all while building a seamless China-US-EU development bridge.
Services that we cover (and excel at)
Our comprehensive suite of professional services caters to a diverse clientele, ranging from early-stage biotech companies to MNCs.
NMPA Regulatory Strategy & Submissions
Expert support for NMPA pre-IND meetings, IND dossier preparation, and expedited review pathways.
Alignment of global (US/EU) development plans with Chinese regulatory expectations for innovative modalities, including mRNA/DNA therapeutics, bispecific antibodies, monoclonal antibodies, and novel vaccines, etc.
Proven success in securing timely NMPA approvals while minimizing regulatory risks.
China Bridging Studies
Full end-to-end leadership of China bridging trials post-NMPA IND approval.
Protocol development, site selection in top-tier hospitals, CRO governance, safety monitoring, and data integration with global programs.
Rapid initiation and high-quality execution tailored for US/EU sponsors entering the China market.
Clinical Development Strategy & Planning
Tailored China and multi-regional clinical development strategies (MRCTs) across oncology, immunology, respiratory, metabolic, rare diseases, and infectious diseases, etc.
Clinical positioning, target indication prioritization, and seamless integration into global development pathways.
Strategic advice on innovative drug modalities, including nucleic acid therapeutics, biologics, and small molecules, etc.
Clinical Trial Operations & Execution
Hands-on management of Phase I–III multi-center trials in China
Site activation, investigator engagement, rapid patient enrollment, medical monitoring, pharmacovigilance, and data oversight
Delivery of high-quality, GCP-compliant trial execution on time and within budget
CRO & Vendor Management
Strategic selection, contracting, and performance management of leading China-based CROs and vendors.
Full lifecycle oversight with regular governance meetings and quality control.
Cost-efficient solutions specifically designed for Western biotech companies operating in China.
KOL Engagement & Investigator-Initiated Trials (IITs)
Access to extensive networks of leading Chinese Key Opinion Leaders and top tertiary hospitals.
Facilitation of scientific advisory boards, KOL consultations, and successful IIT collaborations.
Generation of early clinical data and strong academic partnerships in China.
Successful Cases
Selected highlights demonstrating our ability to accelerate clinical development and secure regulatory milestones for global biotech companies in the China market.
China Phase I Bridging Trial – Gut-Enriched AhR Agonist (Ulcerative Colitis)
- Client: A pre-A round US/China clinical-stage biotech
- We led full clinical operations for the China Phase I bridging trial immediately following NMPA IND approval. Responsibilities included protocol development, top-tier site selection, investigator relationships, CRO governance, AE/safety monitoring, and ongoing data oversight.
- Result: High-quality, on-time execution of the bridging study, enabling seamless integration with the ongoing US Phase I program for refractory ulcerative colitis.
Études Newsletter
- A world of thought-provoking articles.
- Case studies that celebrate architecture.
- Exclusive access to design insights.
“Études has saved us thousands of hours of work and has unlocked insights we never thought possible.”
Annie Steiner
CEO, Greenprint
Watch, Read, Listen
Join 900+ subscribers
Stay in the loop with everything you need to know.
China Regulatory and Clinical Consultancy 